ITEM VIEW

HIV evolution and diversity in ART-treated patients

dc.contributor.authorVan Zyl, Gerten_ZA
dc.contributor.authorBale, Michael J.en_ZA
dc.contributor.authorKearney, Mary F.en_ZA
dc.date.accessioned2018-02-05T05:31:50Z
dc.date.available2018-02-05T05:31:50Z
dc.date.issued2018-01-30
dc.identifier.citationVan Zyl, G., Bale, M. J. & Kearney, M. F. 2018. HIV evolution and diversity in ART-treated patients. Retrovirology, 15:14, doi:10.1186/s12977-018-0395-4
dc.identifier.issn1742-4690 (online)
dc.identifier.otherdoi:10.1186/s12977-018-0395-4
dc.descriptionCITATION: Van Zyl, G., Bale, M. J. & Kearney, M. F. 2018. HIV evolution and diversity in ART-treated patients. Retrovirology, 15:14, doi:10.1186/s12977-018-0395-4.
dc.descriptionThe original publication is available at https://retrovirology.biomedcentral.com
dc.description.abstractCharacterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity prior to ART and how it is affected by suppressive ART, the debate on viral replication and evolution in the presence of ART, HIV compartmentalization across various tissues, and mechanisms for the emergence of drug resistance. It also describes how CD4+ T cells that were likely infected with latent proviruses prior to initiating treatment can proliferate before and during ART, providing a renewable source of infected cells despite therapy. Some expanded cell clones carry intact and replication-competent proviruses with a small fraction of the clonal siblings being transcriptionally active and a source for residual viremia on ART. Such cells may also be the source for viral rebound after interrupting ART. The identical viral sequences observed for many years in both the plasma and infected cells of patients on long-term ART are likely due to the proliferation of infected cells both prior to and during treatment. Studies on HIV diversity may reveal targets that can be exploited in efforts to eradicate or control the infection without ART.
dc.description.sponsorshipNational Cancer Institute (Intramural) and National Institutes of Health (Grant No. 1U01AI116138-01)
dc.description.urihttps://retrovirology.biomedcentral.com/articles/10.1186/s12977-018-0395-4
dc.format.extent12 pages
dc.language.isoen_ZA
dc.publisherBioMed Central
dc.subjectHIV infections -- Genetic aspectsen_ZA
dc.subjectAntiretroviral agentsen_ZA
dc.titleHIV evolution and diversity in ART-treated patientsen_ZA
dc.typeArticleen_ZA
dc.date.updated2018-02-04T04:20:27Z
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyright


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW